Literature DB >> 3901725

Mixed angina pectoris.

A Maseri, S Chierchia, J C Kaski.   

Abstract

Patients who present with episodes of angina caused both by an increase in oxygen demand and by transient impairment of supply have a mixed form of angina. Distinctive clinical features allow the classification of patients in everyday practice. At one end of the spectrum are patients who have angina only and always when they exercise beyond an essentially fixed level; their angina is fairly predictable and has been termed secondary angina. At the other end of the spectrum are patients who have a normal exercise tolerance but have angina at rest or during activities usually well tolerated that must be caused by a transient impairment of coronary blood flow; their angina is typically unpredictable and has been termed primary angina. We adopted the term primary to emphasize the possible existence of multiple causes of impairment of coronary flow, which together are to be contrasted with the traditional prevailing concept of angina being secondary to excessive increase in demand. In between these ends of the spectrum are most of the patients with angina pectoris encountered in clinical practice: they have a rather predictable ceiling of exercise that they cannot exceed without developing angina, but they also have a variable proportion of unpredictable anginal attacks that occur spontaneously or at levels of activity that are usually well tolerated. We introduced the concept of mixed forms of angina when we became aware that the same patient could experience angina both as a result of an excessive increase in myocardial demand, i.e., secondary angina, and as a result of the transient impairment of coronary blood flow supply, i.e., primary angina.

Entities:  

Mesh:

Year:  1985        PMID: 3901725     DOI: 10.1016/0002-9149(85)91173-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Indications for balloon coronary angioplasty and coronary artery bypass surgery. An evolving discussion.

Authors:  P Angelini
Journal:  Tex Heart Inst J       Date:  1991

2.  Pharmacology of the coronary circulation.

Authors:  J C Sill
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

Review 3.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 4.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  [Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy].

Authors:  M Leschke; F C Schoebel; T W Jax; C M Schannwell; R Marx; B E Strauer
Journal:  Herz       Date:  1997-10       Impact factor: 1.443

Review 6.  Management of vasospastic angina--role of nicorandil.

Authors:  J C Kaski
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

7.  Effect of stimulation of anterior hypothalamic area on urinary bladder function of the anesthetized rat.

Authors:  Isabel Rocha; Luís Silva-Carvalho; K Michael Spyer
Journal:  Clin Auton Res       Date:  2004-08       Impact factor: 4.435

8.  Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris.

Authors:  Sylvie Chabaud; Pascal Girard; Patrice Nony; Jean-Pierre Boissel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

Review 9.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

10.  Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina.

Authors:  T E Meyer; C Adnams; P Commerford
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.